[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnD9K9pCNnpHaQNo5G5t9Ku4HWU9s47_TRpZlzr4oTIw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"Solventum US LLC",[4],63,false,2,4,9557,0,47,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Healthy",7,{"name":18,"count":19},"Dental Caries",6,{"name":21,"count":22},"Dental Decay",3,{"name":24,"count":8},"Venous Ulcer",{"name":26,"count":8},"Surgical Skin Preparation",{"name":28,"count":8},"Tooth Decay",{"name":30,"count":31},"Caries",1,{"name":33,"count":31},"Catheterization",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,94,120,138,156,183,201,227,245,282,308,326,344,362,380,398,416,434,452,480,506,524,569,593,620,638],{"intervention":44,"totalTrials":22,"cells":45},"ChloraPrep",{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":64,"PHASE4":80,"NA":92},{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[52],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":62},"NCT03155178","In Vivo Preoperative Skin Preparation Persistence Evaluation","COMPLETED",[38],"2017-04-25","2016-12-05",69,[61],"Bacterial Recovery of Skin Flora Post-product Application",[63,44],"3M CHG\u002FIPA Prep",{"trials":65,"activeCount":11},[66],{"nctId":67,"briefTitle":68,"status":69,"phases":70,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":76},"NCT01968356","In-vivo Efficacy Study of Patient Preoperative Preps","TERMINATED",[39],"2014-01","2013-10",171,[75],"Skin Flora Bacterial Reduction Post-product Application",[77,78,44,79],"3M CHG\u002FIPA Prep Colorless","3M CHG\u002FIPA Prep Tint","Saline",{"trials":81,"activeCount":11},[82],{"nctId":83,"briefTitle":84,"status":55,"phases":85,"primaryCompletion":86,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":90},"NCT01290978","Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin",[40],"2010-03","2010-02",22,[15],[44,91],"DuraPrep",{"trials":93,"activeCount":11},[],{"intervention":95,"totalTrials":31,"cells":96},"mupirocin calcium ointment, 2%",{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":118},{"trials":98,"activeCount":11},[],{"trials":100,"activeCount":11},[],{"trials":102,"activeCount":11},[],{"trials":104,"activeCount":11},[],{"trials":106,"activeCount":11},[107],{"nctId":108,"briefTitle":109,"status":55,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT01313182","Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin",[40],"2012-09","2011-03",1874,[115],"Surgical Site Infection",[95,117],"3M Skin and Nasal Antiseptic",{"trials":119,"activeCount":11},[],{"intervention":117,"totalTrials":31,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":136},{"trials":123,"activeCount":11},[],{"trials":125,"activeCount":11},[],{"trials":127,"activeCount":11},[],{"trials":129,"activeCount":11},[],{"trials":131,"activeCount":11},[132],{"nctId":108,"briefTitle":109,"status":55,"phases":133,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":134,"interventions":135},[40],[115],[95,117],{"trials":137,"activeCount":11},[],{"intervention":91,"totalTrials":31,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":154},{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[],{"trials":147,"activeCount":11},[],{"trials":149,"activeCount":11},[150],{"nctId":83,"briefTitle":84,"status":55,"phases":151,"primaryCompletion":86,"completion":86,"start":87,"enrollment":88,"conditions":152,"interventions":153},[40],[15],[44,91],{"trials":155,"activeCount":11},[],{"intervention":157,"totalTrials":31,"cells":158},"hand antiseptic with CHG and alcohol",{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":181},{"trials":160,"activeCount":11},[],{"trials":162,"activeCount":11},[],{"trials":164,"activeCount":11},[],{"trials":166,"activeCount":11},[],{"trials":168,"activeCount":11},[169],{"nctId":170,"briefTitle":171,"status":55,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},"NCT02258412","Evaluation of Two Hand Hygiene Products in ICUs",[40],"2015-01","2015-02","2014-10",51,[178],"Hand Hygiene Effectiveness",[157,180],"Alcohol hand sanitizer foam",{"trials":182,"activeCount":11},[],{"intervention":180,"totalTrials":31,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":199},{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[],{"trials":190,"activeCount":11},[],{"trials":192,"activeCount":11},[],{"trials":194,"activeCount":11},[195],{"nctId":170,"briefTitle":171,"status":55,"phases":196,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":197,"interventions":198},[40],[178],[157,180],{"trials":200,"activeCount":11},[],{"intervention":202,"totalTrials":31,"cells":203},"Avagard",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":225},{"trials":205,"activeCount":11},[],{"trials":207,"activeCount":11},[],{"trials":209,"activeCount":11},[],{"trials":211,"activeCount":11},[],{"trials":213,"activeCount":11},[214],{"nctId":215,"briefTitle":216,"status":55,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT00731042","A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects",[40],"2008-04","2008-07","2008-03",33,[15],[202,224],"Purell Surgical Scrub",{"trials":226,"activeCount":11},[],{"intervention":224,"totalTrials":31,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":243},{"trials":230,"activeCount":11},[],{"trials":232,"activeCount":11},[],{"trials":234,"activeCount":11},[],{"trials":236,"activeCount":11},[],{"trials":238,"activeCount":11},[239],{"nctId":215,"briefTitle":216,"status":55,"phases":240,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":241,"interventions":242},[40],[15],[202,224],{"trials":244,"activeCount":11},[],{"intervention":246,"totalTrials":8,"cells":247},"Normal saline",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":278,"NA":280},{"trials":249,"activeCount":11},[],{"trials":251,"activeCount":11},[],{"trials":253,"activeCount":11},[],{"trials":255,"activeCount":11},[256,268],{"nctId":257,"briefTitle":258,"status":55,"phases":259,"primaryCompletion":260,"completion":260,"start":72,"enrollment":261,"conditions":262,"interventions":264},"NCT01968707","In-vivo Efficacy Study of Patient Pre-operative Preps",[39],"2014-06",426,[263],"Bacterial Reduction on Skin Flora Post-product Application",[265,246,266,267],"ChloraPrep Hi-Lite Orange","3M CHG\u002FIPA Prep Tint 10.5-mL","3M CHG\u002FIPA Prep Tint 26-mL",{"nctId":269,"briefTitle":270,"status":55,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT04756154","Efficacy Study of Patient Preoperative Preps In-vivo",[39],"2021-04-28","2020-07-06",154,[26],[277,246],"CHG\u002FIPA Surgical skin preparation",{"trials":279,"activeCount":11},[],{"trials":281,"activeCount":11},[],{"intervention":283,"totalTrials":31,"cells":284},"Chlorhexidine gluconate",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":304,"NA":306},{"trials":286,"activeCount":11},[],{"trials":288,"activeCount":11},[],{"trials":290,"activeCount":11},[],{"trials":292,"activeCount":11},[293],{"nctId":294,"briefTitle":295,"status":55,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT00516906","Clinical Performance of a Chlorhexidine Antimicrobial Dressing",[38,39],"2007-12","2008-01","2007-10",68,[33],[283,303],"Transparent Adhesive Dressing",{"trials":305,"activeCount":11},[],{"trials":307,"activeCount":11},[],{"intervention":303,"totalTrials":31,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":322,"NA":324},{"trials":311,"activeCount":11},[],{"trials":313,"activeCount":11},[],{"trials":315,"activeCount":11},[],{"trials":317,"activeCount":11},[318],{"nctId":294,"briefTitle":295,"status":55,"phases":319,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":320,"interventions":321},[38,39],[33],[283,303],{"trials":323,"activeCount":11},[],{"trials":325,"activeCount":11},[],{"intervention":265,"totalTrials":31,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":340,"NA":342},{"trials":329,"activeCount":11},[],{"trials":331,"activeCount":11},[],{"trials":333,"activeCount":11},[],{"trials":335,"activeCount":11},[336],{"nctId":257,"briefTitle":258,"status":55,"phases":337,"primaryCompletion":260,"completion":260,"start":72,"enrollment":261,"conditions":338,"interventions":339},[39],[263],[265,246,266,267],{"trials":341,"activeCount":11},[],{"trials":343,"activeCount":11},[],{"intervention":266,"totalTrials":31,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":352,"PHASE4":358,"NA":360},{"trials":347,"activeCount":11},[],{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"trials":353,"activeCount":11},[354],{"nctId":257,"briefTitle":258,"status":55,"phases":355,"primaryCompletion":260,"completion":260,"start":72,"enrollment":261,"conditions":356,"interventions":357},[39],[263],[265,246,266,267],{"trials":359,"activeCount":11},[],{"trials":361,"activeCount":11},[],{"intervention":267,"totalTrials":31,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":376,"NA":378},{"trials":365,"activeCount":11},[],{"trials":367,"activeCount":11},[],{"trials":369,"activeCount":11},[],{"trials":371,"activeCount":11},[372],{"nctId":257,"briefTitle":258,"status":55,"phases":373,"primaryCompletion":260,"completion":260,"start":72,"enrollment":261,"conditions":374,"interventions":375},[39],[263],[265,246,266,267],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[],{"intervention":77,"totalTrials":31,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":394,"NA":396},{"trials":383,"activeCount":11},[],{"trials":385,"activeCount":11},[],{"trials":387,"activeCount":11},[],{"trials":389,"activeCount":11},[390],{"nctId":67,"briefTitle":68,"status":69,"phases":391,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":392,"interventions":393},[39],[75],[77,78,44,79],{"trials":395,"activeCount":11},[],{"trials":397,"activeCount":11},[],{"intervention":78,"totalTrials":31,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":412,"NA":414},{"trials":401,"activeCount":11},[],{"trials":403,"activeCount":11},[],{"trials":405,"activeCount":11},[],{"trials":407,"activeCount":11},[408],{"nctId":67,"briefTitle":68,"status":69,"phases":409,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":410,"interventions":411},[39],[75],[77,78,44,79],{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"intervention":79,"totalTrials":31,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":430,"NA":432},{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[],{"trials":425,"activeCount":11},[426],{"nctId":67,"briefTitle":68,"status":69,"phases":427,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":428,"interventions":429},[39],[75],[77,78,44,79],{"trials":431,"activeCount":11},[],{"trials":433,"activeCount":11},[],{"intervention":277,"totalTrials":31,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":448,"NA":450},{"trials":437,"activeCount":11},[],{"trials":439,"activeCount":11},[],{"trials":441,"activeCount":11},[],{"trials":443,"activeCount":11},[444],{"nctId":269,"briefTitle":270,"status":55,"phases":445,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":446,"interventions":447},[39],[26],[277,246],{"trials":449,"activeCount":11},[],{"trials":451,"activeCount":11},[],{"intervention":63,"totalTrials":8,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":455,"activeCount":11},[],{"trials":457,"activeCount":11},[],{"trials":459,"activeCount":11},[460,464],{"nctId":53,"briefTitle":54,"status":55,"phases":461,"primaryCompletion":57,"completion":57,"start":58,"enrollment":59,"conditions":462,"interventions":463},[38],[61],[63,44],{"nctId":465,"briefTitle":466,"status":55,"phases":467,"primaryCompletion":468,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":473},"NCT03681990","In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area",[38],"2017-07-04","2017-06-06",28,[26,472],"Surgical Procedure, Unspecified",[63],{"trials":475,"activeCount":11},[],{"trials":477,"activeCount":11},[],{"trials":479,"activeCount":11},[],{"intervention":481,"totalTrials":31,"cells":482},"3M CHG\u002FIPA Surgical Skin Preparation - Abdominal Region",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":500,"PHASE4":502,"NA":504},{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[489],{"nctId":490,"briefTitle":491,"status":55,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT02447497","In Vivo Patient Preoperative Skin Prep Persistence",[38],"2015-04","2015-03",27,[497],"Bacterial Recovery of Skin Flora Post-Product Application",[481,499],"3M CHG\u002FIPA Surgical Skin Preparation - Inguinal Region",{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[],{"intervention":499,"totalTrials":31,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":509,"activeCount":11},[],{"trials":511,"activeCount":11},[],{"trials":513,"activeCount":11},[514],{"nctId":490,"briefTitle":491,"status":55,"phases":515,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":516,"interventions":517},[38],[497],[481,499],{"trials":519,"activeCount":11},[],{"trials":521,"activeCount":11},[],{"trials":523,"activeCount":11},[],{"intervention":525,"totalTrials":22,"cells":526},"Tiotropium",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[531,541,552],{"nctId":532,"briefTitle":533,"status":55,"phases":534,"primaryCompletion":535,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":540},"NCT02627625","Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products",[37],"2016-03","2016-06","2015-11",31,[15],[525],{"nctId":542,"briefTitle":543,"status":55,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT02676297","Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products",[37],"2016-05","2016-07","2016-01",26,[15],[551],"tiotropium",{"nctId":553,"briefTitle":554,"status":55,"phases":555,"primaryCompletion":556,"completion":557,"start":545,"enrollment":558,"conditions":559,"interventions":560},"NCT03302065","Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference",[37],"2016-09","2017-01",38,[15],[525],{"trials":562,"activeCount":11},[],{"trials":564,"activeCount":11},[],{"trials":566,"activeCount":11},[],{"trials":568,"activeCount":11},[],{"intervention":570,"totalTrials":31,"cells":571},"tiotropium pMDI",{"EARLY_PHASE1":572,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":589,"NA":591},{"trials":573,"activeCount":11},[574],{"nctId":575,"briefTitle":576,"status":55,"phases":577,"primaryCompletion":578,"completion":579,"start":57,"enrollment":580,"conditions":581,"interventions":582},"NCT03155204","Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product",[36],"2018-01-21","2018-03-19",46,[15],[570],{"trials":584,"activeCount":11},[],{"trials":586,"activeCount":11},[],{"trials":588,"activeCount":11},[],{"trials":590,"activeCount":11},[],{"trials":592,"activeCount":11},[],{"intervention":594,"totalTrials":31,"cells":595},"No SLS toothpaste",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":597,"activeCount":11},[],{"trials":599,"activeCount":11},[],{"trials":601,"activeCount":11},[],{"trials":603,"activeCount":11},[],{"trials":605,"activeCount":11},[],{"trials":607,"activeCount":11},[608],{"nctId":609,"briefTitle":610,"status":69,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT04601103","3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes",[41],"2020-03-10","2020-01-06",53,[616],"Oral Mucosal Disorder",[594,618,619],"Medium SLS toothpaste","High SLS toothpaste",{"intervention":618,"totalTrials":31,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":623,"activeCount":11},[],{"trials":625,"activeCount":11},[],{"trials":627,"activeCount":11},[],{"trials":629,"activeCount":11},[],{"trials":631,"activeCount":11},[],{"trials":633,"activeCount":11},[634],{"nctId":609,"briefTitle":610,"status":69,"phases":635,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":636,"interventions":637},[41],[616],[594,618,619],{"intervention":619,"totalTrials":31,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":641,"activeCount":11},[],{"trials":643,"activeCount":11},[],{"trials":645,"activeCount":11},[],{"trials":647,"activeCount":11},[],{"trials":649,"activeCount":11},[],{"trials":651,"activeCount":11},[652],{"nctId":609,"briefTitle":610,"status":69,"phases":653,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":654,"interventions":655},[41],[616],[594,618,619]]